Introduction {#s1}
============

Pheochromocytomas and paragangliomas (PCC/PGLs) are highly genetically related, neuroendocrine tumors that have been listed as rare diseases by the World Health Organization ([@B30]). Adrenal chromaffin cells secrete catecholamines and give rise to PCC/PGLs ([@B29]; [@B28]; [@B8]). Approximately 90% of chromaffin cells are present in the adrenal medulla and tumors that occur here are termed PCC ([@B6]). The other 10% of cells are located outside the adrenal medulla, such as in the heart, bladder, and neck, and these tumor cases are called extra-adrenal PCC or PGL ([@B5]). The major clinical manifestations of PCC/PGLs are unpredictable hypertension, cardiovascular crisis, hyperhidrosis, palpitations, and elevated basal metabolic rate, which are induced by the excessive secretion of catecholamines ([@B11]; [@B24]). PCC/PGLs are also involved in some severe syndromes such as von Hippel-Lindau disease ([@B19]), multiple endocrine neoplasia (type I and II), and neurofibromatosis ([@B32]). If patients fail to undergo proper treatment in time, their 5-year survival rate drops below 40% due to excessive catecholamine secretion as well as the development of chemotherapy and radiation therapy resistance ([@B36]; [@B35]; [@B14]). As PCC/PGLs are among the most genetically related human cancers with 60% of patients showing family aggregation ([@B7]; [@B18]; [@B10]), genetic screening is of great value and significance for the diagnosis and prevention of PCC/PGLs ([@B2]). Moreover, over 15 genomic and transcriptomic molecules reported to regulate PCC/PGL development, such as *SDHx, VHL, TMEM127, HRAS, FGFR1, ATRX, RET, EPAS1, MAX, EGLN1*, and *NF1*, were found mutated in the germline of PCC/PGLs patients ([@B8]; [@B3]; [@B32]; [@B35]; [@B33]; [@B31]).

Circular RNAs (circRNAs) are highly evolutionarily conserved, regulatory, noncoding RNAs that play significant roles in various biological and pathological processes, such as gene translation, transcription, and tumor genesis and development; they also act as microRNA (miRNA) sponges. CircRNAs have a stable loop structure that lacks a 5' cap and 3' tail and are thus not easily degraded by RNase. Under specific circumstances, some circRNAs can open their loop structure for translation ([@B25]; [@B20]). Moreover, circRNAs exhibit abnormal expression in numerous cancer types, including liver, stomach, breast, ovarian, and oral cancers; therefore, they have been considered novel biomarkers for tumor screening and are potential therapeutic targets ([@B9]; [@B4]; [@B26]; [@B37]).

Considering the high genetic relevance and neuroendocrine characteristics of PCC/PGLs, we speculated that circRNAs may play important roles in regulating the development of PCC/PGLs. Previous studies have identified multiple key mediators for the pathogenesis of PCC/PGLs ([@B32]; [@B33]; [@B10]), such as genetic alterations of *SHDx* and *VHL*, but whether these components are modulated by circRNAs remains unknown. Therefore, we performed RNA sequencing using tumor tissues and para-cancerous normal adrenal medulla tissues from PCC/PGLs patients to examine the aberrant expression of circRNAs and miRNAs. The data were evaluated by comparative analyses of reference sequences and tissue specificity was predicted. circRNAs with significantly altered expression were further screened and their binding sites to miRNAs predicted. In addition, we performed gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses using these differentially expressed circRNAs and mapped their interaction networks.

Materials and Methods {#s2}
=====================

Sample Collection {#s2_1}
-----------------

Tumor and adjacent normal adrenal medulla specimens were collected during surgery from 40 PCC/PGL patients who underwent laparoscopic resection between February 2018 and September 2018 in Xianya Hospital. Detailed patient information is listed in [**Table 1**](#T1){ref-type="table"}. Seven PCC/PGL patients were randomly selected for RNA sequencing of their tissues while the other 33 PCC/PGL patients were used to validate the sequencing outcomes. All samples were validated by pathological examination and were frozen and stored immediately in liquid nitrogen until further use. Peripheral blood of 16 PCC/PGL patients and 16 healthy donors was collected and stored immediately at −80°C. All patients were primarily diagnosed with PCC/PGLs *via* imaging (computerized tomography and color ultrasound) and laboratory examination (urine vanillylmandelic acid), and did not undergo any treatments before surgery. All patients signed informed consent forms before the surgery and study, which was approved by the Ethics Committee of Xiangya Hospital of Central South University.

###### 

Characteristics of the seven pheochromocytomas and paragangliomas (PCC/PGL) patients whose samples were used for RNA sequencing.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  e   Sex      Age   Blood pressure before surgery   VMA (U)   Pathological diagnosis        Immunohistochemistry                                                                       Genotype\
                                                                                                                                                                                        (gene mutation)
  --- -------- ----- ------------------------------- --------- ----------------------------- ------------------------------------------------------------------------------------------ -----------------
  1   Female   53    230/100                         80.1      PCC (right adrenal gland)     CgA (+), Syn (+), S-100 (−), SF-1 (−), Ki67 (1%+), inhibin (−), Melan-A (−), P53 (−)       HRAS

  2   Female   52    114/79                          34.8      PCC (right adrenal gland)     CgA (+), Syn (+), S-100 (−), SF-1 (−), Ki67 (1%+), inhibin (−), Melan-A (−), P53 (−)       RET

  3   Male     32    140/87                          Normal    PCC (left adrenal gland)      CgA (+), Syn (++), S-100 (+), Ki67 (2%+), inhibin (+), Melan-A (-), P53 (−)                VHL

  4   Male     8     210/130                         97/21.6   PCC (double adrenal glands)   CgA (++), Syn (++), S-100 (++), Ki67 (2%+), inhibin (+), Melan-A (−), P53 (−)              RET/VHL

  5   Male     49    129/88                          89.9      PCC (right adrenal gland)     CgA (++), Syn (++), S-100 (++), Ki67 (2%+), inhibin (+), Melan-A (−), P53 (−)              VHL

  6   Male     57    123/72                          40/16.8   PCC (right adrenal gland)     CgA (++), Syn (+), S-100 (+), SF-1 (−), Ki67 (\< 1%+), inhibin (−), Melan-A (−), P53 (−)   HRAS

  7   Female   51    141/83                          58.2      PCC (right adrenal gland)     CgA (++), Syn (+), S-100 (+), SF-1 (−), Ki67 (2%+), inhibin (−), Melan-A (−), P53 (−)      VHL
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

VMA, urine vanillylmandelic acid.

Total Ribonucleic Acid Extraction {#s2_2}
---------------------------------

Frozen samples and peripheral blood were taken out of liquid nitrogen storage and immediately mixed with TRIzol reagent (Ambion, Austin, TX). Tissues were homogenized and lysed in TRIzol reagent, after which total RNAs were extracted according to manufacturer's instructions.

Ribonucleic Acid Quantification and Qualification {#s2_3}
-------------------------------------------------

Electrophoresis on 2% agarose gels was used to determine whether the total RNAs were degraded or contaminated. A NanoPhotometer^®^ spectrophotometer (IMPLEN, Westlake Village, CA) and Qubit^®^ RNA Assay Kit in Qubit^®^2.0 Fluorometer (Life Technologies, Carlsbad, CA) were used to detect the purity and concentration of RNA, respectively. The RNA Nano6000 Assay Kit (Agilent Technologies, Santa Clara, CA) was used to assess RNA integrity.

Ribonucleic Acid Library Construction, Clustering, and Sequencing {#s2_4}
-----------------------------------------------------------------

We used approximately 5 ug of total RNA for each sample and used the Ribo-Zero™ rRNA Removal Kit (Illumina, San Diego, CA) to eliminate ribosomal RNA interference according to manufacturer's instructions. The residue was purified by two rounds of ethanol precipitation, after which divalent cations were used to splice the remaining RNAs into small fragments under high temperature. The small RNA fragments were reverse-transcribed to complementary DNA (cDNA) and second strand cDNA was synthesized using *Escherichia coli* DNA polymerase I, deoxyuridine triphosphates (dUTPs), and RNase H. After adding an A-base to the 3ʹ ends of each cDNA fragment and ligating to the NEBNext Adaptor \[New England Biolabs (NEB), Ipswich, MA\], we purified the library using the AMPureXP system (Beckman Coulter, Brea, CA) and prepared for hybridization. Next, approximately 2 µl USER enzyme (NEB) was added to the cDNA buffer for PCR. TruSeq SR Cluster Kit v3-cBot-HS (Illumia) was used to cluster the samples on the cBot Cluster Generation System. Finally, the Illumina HiSeq 2500/2000 sequencing platform was used to sequence the libraries (150 bp paired-end reads) after cluster generation. Sequencing data were analyzed against the reference genome, after which the circRNAs were filtered out. The software Find_circ and CIRI2 ([@B44]) were used to identify circRNAs;

Identification of Differentially Expressed Circular Ribonucleic Acids, Microribonucleic Acids, and Messenger Ribonucleic Acids {#s2_5}
------------------------------------------------------------------------------------------------------------------------------

DESeq R package(1.8.3) (<https://www.bioconductor.org>) was used to perform read-count analysis of differentially expressed RNAs \[circRNAs, miRNAs, and messenger RNAs (mRNAs)\]. An adjusted p value of \< 0.05 was considered statistically significant and related RNAs were recognized as differentially expressed. miRanda software ([https://omictools.com › miranda-tool](https://omictools.com › miranda-tool)) was used to predict the target miRNA binding sites of circRNAs.

Gene Ontology and Kyoto Encyclopedia of Genes and Genomes Pathway Enrichment Analysis {#s2_6}
-------------------------------------------------------------------------------------

Gene Ontology (GO) enrichment analysis (<http://www.webgestalt.org>), an online software, was used to predict the molecular function, biological process, cellular components, and location of the target miRNAs of differentially expressed circRNAs. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis (<http://kobas.cbi.pku.edu.cn/anno_iden.php>) was used to predict the possible metabolic pathways of some differentially expressed circRNAs Enrichment with p \< 0.05 was regarded as statistically significant.

Real Time Polymerase Chain Reaction Analysis {#s2_7}
--------------------------------------------

Reverse transcription of total RNA was performed using the Superscript IV Reverse Transcriptase (Thermo Fisher Scientific, Waltham, MA) at 50°C for 15 min to obtain cDNA. Real-time PCR was then performed using SYBR Green Reagent on an ABI PRISM 7500 Fast Real-Time PCR System (Thermo Fisher Scientific, Waltham, MA). Primers used for qPCR were synthesized at Sango Biotech (Shanghai, China) and are listed in [**Supplementary Table 6**](#SM1){ref-type="supplementary-material"}. Relative expression of the different genes was normalized to β-actin expression, and arbitrary units were used to display normalized gene expression. The data were analyzed using the 2^−ΔΔCt^ method.

Circular Ribonucleic Acid-Microribonucleic Acid-Messenger Ribonucleic Acid Coding-Noncoding Gene Co-Expression Network Analysis {#s2_8}
-------------------------------------------------------------------------------------------------------------------------------

Cytoscape software ([@B34]) was used to construct the circRNA-miRNA-mRNA networks.

Statistical Analysis {#s2_9}
--------------------

All data were analyzed using SPSS version 23 (IBM, Armonk, NY) and GraphPad Prism 5 (GraphPad Software Inc., La Jolla, CA). A paired Student's *t*-test was used to test significance of the results and p values \< 0.05 were considered statistically significant.

Results {#s3}
=======

Circular Ribonucleic Acid Expression Profiles of Human Pheochromocytomas and Paragangliomas Tumor Tissues {#s3_1}
---------------------------------------------------------------------------------------------------------

The density distribution of circRNAs on the chromosome is shown in [**Figure 1A**](#f1){ref-type="fig"}. (Chromosome 1--9 and X were shown in the panel, details of circRNAs on all the chromosome can be seen in [**Supplementary Table 1**](#SM1){ref-type="supplementary-material"} the density distribution of circRNAs on all the chromosome). Different sources (exons, introns, and intergenic regions) of circRNAs were counted ([**Figure 1B**](#f1){ref-type="fig"}) because circRNAs can be acquired from the splicing of exons and introns. We thus speculated that most circRNAs in PCC/PGLs are obtained from the splicing of exons in both tumor and adjacent normal tissues. Next, we analyzed the length distribution of circRNAs in different patient samples ([**Figure 1C**](#f1){ref-type="fig"}) and found that the majority of circRNAs were between 0 and 2,000 nt. Additionally, we mapped the transcription per million (TPM) distribution graph for an overall examination of the gene expression pattern in different samples ([**Figure 1D**](#f1){ref-type="fig"}).

![Profiles of circular RNAs (circRNAs) identified in pheochromocytomas and paragangliomas (PCC/PGLs). **(A)** Density distribution of circRNAs on the chromosome. **(B)** The different sources of circRNAs (exons, introns, and intergenic regions). **(C)** Length distribution graph of circRNAs in different patient samples. **(D)** Transcription per million (TPM) distribution graph. (RNASEQC: tumor samples of PCC/PGLs patients for RNA sequencing, RNASEQN: normal adrenal medulla tissues of PCC/PGLs patients for RNA sequencing).](fgene-11-00015-g001){#f1}

Identification and Validation of Differentially Expressed Circular Ribonucleic Acid in Pheochromocytomas and Paragangliomas {#s3_2}
---------------------------------------------------------------------------------------------------------------------------

A total of 367 differentially expressed circRNAs were identified after RNA sequencing and qualification, among which 255 were upregulated and 112 were downregulated. The top 20 differentially expressed circRNAs are listed in [**Table 2**](#T2){ref-type="table"}. We next performed hierarchical cluster analysis of differentially expressed circRNAs and acquired the volcano map (log2FoldChange \> 1; adjusted p \< 0.05) and heat map for these samples ([**Figures 2A, B**](#f2){ref-type="fig"}). We selected the top 11 differentially expressed circRNAs and conducted real-time qPCR using the other 33 pairs of PCC/PGLs samples to test if these circRNAs show the same relative expression as in the RNA sequencing data; information and genotype of the 33 patients is available in [**Supplementary Table 2**](#SM1){ref-type="supplementary-material"} information and genotype of the 33 patients and the primer sequences for each circRNA is listed in [**Supplementary Table 6**](#SM1){ref-type="supplementary-material"}. As shown in [**Figure 2C--E**](#f2){ref-type="fig"}, expression levels of hsa_circ_0000567, hsa_circ_0002897, hsa_circ_0004473, hsa_circ_0000972, hsa_circ_0000825, hsa_circ_0003265, and hsa_circ_0007279 were significantly higher in tumor tissues than in para-cancerous tissues, whereas the expression of hsa_circ_0056892, hsa_circ_0019773, and hsa_circ_0007444 was markedly downregulated in tumors tissues compared with adjacent tissues. However, there was no difference in hsa_circ_0001573 expression levels *via* real-time PCR. Overall, these data indicate that the sequencing outcomes were reliable and that these altered circRNAs may play important roles in tumor genesis or pathological processes and can serve as potential biomarkers or therapeutic targets.

###### 

The top 20 differentially expressed circular ribonucleic acids (circRNAs) in pheochromocytomas and paragangliomas.

  ID                   PHEOC_readcount   PHEON_readcount   log~2~FoldChange   p-val      p-adj
  -------------------- ----------------- ----------------- ------------------ ---------- ----------
  hsa_circ_0003265     74.30462          8.195594          3.1329             1.77E−15   5.90E−12
  novel_circ_0010710   0.379333          48.06986          −6.1755            1.78E−14   2.96E−11
  hsa_circ_0007444     72.18526          204.4537          −1.4916            9.31E−12   1.03E−08
  hsa_circ_0019773     3.831636          32.74755          −2.9191            5.55E−11   4.62E−08
  hsa_circ_0056892     1.305188          22.93686          −3.7578            1.05E−10   7.02E−08
  novel_circ_0018500   65.11106          5.843535          3.3556             1.87E−10   1.04E−07
  hsa_circ_0000825     20.28743          0.373391          5.4407             3.32E−10   1.58E−07
  hsa_circ_0000972     40.7458           2.594112          3.8421             6.92E−10   2.88E−07
  hsa_circ_0007279     23.44449          1.258304          4.047              1.15E−09   4.25E−07
  hsa_circ_0001573     13.74913          46.72078          −1.6969            1.83E−09   5.53E−07
  novel_circ_0012887   46.11258          2.453379          4.0571             1.68E−09   5.53E−07
  novel_circ_0013677   10.2773           42.46868          −1.9987            2.41E−09   6.68E−07
  novel_circ_0013545   29.82766          1.865443          3.8841             3.63E−09   9.30E−07
  hsa_circ_0072391     2.601763          47.52957          −3.8994            4.27E−09   1.02E−06
  novel_circ_0000068   2.383841          23.84816          −3.1286            9.48E−09   2.10E−06
  novel_circ_0004082   24.64715          0.373391          5.4857             1.10E−08   2.30E−06
  hsa_circ_0001633     132.6587          12.47332          3.2827             1.55E−08   3.05E−06
  hsa_circ_0015454     0.891954          14.12767          −3.6241            3.43E−08   6.33E−06
  hsa_circ_0077736     7.951543          33.60178          −2.0141            3.61E−08   6.33E−06
  hsa_circ_0001678     27.54639          1.488962          3.8505             5.07E−08   8.44E−06

PHEOC, tumor tissues of PCC/PGLs patients; PHEON, normal adrenal medulla tissues of PCC/PGLs patients; p-adj, adjust p value, which is designed to control the expected proportion of "discoveries" (rejected null hypotheses) that are false (incorrect rejections).

![Identification and validation of differentially expressed circular RNAs (circRNAs) in pheochromocytomas and paragangliomas (PCC/PGLs). **(A)** Heatmap of differentially expressed circRNAs. (RNASEQC, tumor samples of PCC/PGLs patients for RNA sequencing; RNASEQN, normal adrenal medulla tissues of PCC/PGLs patients for RNA sequencing). **(B)** Volcano map of differentially expressed circRNAs; 255 were upregulated and 122 were downregulated. (PHEOC, tumor tissues of PCC/PGLs patients; PHEON, normal adrenal medulla tissues of PCC/PGLs patients.) **(C--E)** Real time PCR validation of the top 11 differentially expressed circRNAs in 33 pairs of PCC/PGL tumor tissues and adjacent tissues.](fgene-11-00015-g002){#f2}

Gene Ontology Enrichment and Analysis of Genes Associated With Differentially Expressed Circular Ribonucleic Acids {#s3_3}
------------------------------------------------------------------------------------------------------------------

After obtaining the differentially expressed circRNAs, we performed GO analysis on the source genes in each group based on the correspondence between circRNAs and their binding miRNAs and source genes ([**Figure 3A**](#f3){ref-type="fig"}). We found that the main biological process terms were related to cell metabolism and transport, such as regulation of cholesterol metabolic process (GO:0090181), positive regulation of ion transport (GO:0043270), regulation of transport (GO:0051049), and regulation of hydrolase activity (GO:0051336). The highest enriched cellular component terms were associated with microtubule (GO:0005874) and microtubule cytoskeleton (GO:0015630). The most enriched molecular function terms were related to histone methyltransferase activity (H3-K36 specific; GO:0046975), transfer RNA (tRNA) (cytosine-5-)-methyltransferase activity (GO:0016428), and tRNA (cytosine) methyltransferase activity (GO:0016427).

GO enrichment results showed that the degree of enrichment of histone methylation-related circRNAs occupied the top positions of molecular function, suggesting that methylation regulation of target genes by circRNAs may play important roles in the pathogenesis of PCC/PGLs. We further performed real-time PCR to analyze the top three histone methylation-related circRNAs in the peripheral blood of 16 PCC/PGL patients (see [**Supplementary Table 3**](#SM1){ref-type="supplementary-material"} information and genotype of the 16 patients) and 16 healthy donors, and found that circRNAs has_circ_0000567, hsa_circ_0002897, ahashsa_circ_0004473 also exhibited relatively high expression levels in PCC/PGL patients compared with healthy donors ([**Figure 3B**](#f3){ref-type="fig"}).

![Gene ontology prediction and validation of histone methylation-related circular RNAs (circRNAs) in peripheral blood. **(A)** Gene ontology analysis of the top enriched molecular function of the differently expressed circRNAs. **(B)** Validation of the top three differentially expressed circRNAs by real time PCR using the peripheral blood of PCC/PGL patients and healthy donors.](fgene-11-00015-g003){#f3}

Prediction and Analysis of the Histone Methylation-Related Circular Ribonucleic Acid-Microribonucleic Acid-Messenger Ribonucleic Acid Coding-Noncoding Gene Co-Expression Network {#s3_4}
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Next, we selected the three histone methylation-related circRNAs (hsa_circ_0000567, hsa_circ_0002897, and hsa_circ_0004473) with the most significant differences to predict and analyze their target miRNAs and mRNAs. The top five target miRNAs and related mRNAs were used to map the coding-noncoding gene co-expression (CNC) network ([**Figure 4A**](#f4){ref-type="fig"}). Notably, the predicted binding miRNAs of the three upregulated circRNAs in PCC/PGL tumor tissues were all downregulated according to the miRNA sequencing data ([**Figure 4B**](#f4){ref-type="fig"} and [**Supplementary Table 4**](#SM1){ref-type="supplementary-material"} the circRNAs-miRNAs binding relationship). Our findings suggest that these histone methylation-related circRNAs act as RNA sponges and regulate their target miRNAs, highlighting their potential as novel therapeutic targets for PCC/PGLs.

![Prediction of histone methylation-related messenger RNAs (miRNAs). **(A)** The coding-noncoding gene co-expression (CNC) prediction network of the top three methylation-related circRNAs (hsa_circ_0000567, hsa_circ_0002897, and hsa_circ_0004473) and their target miRNAs and mRNAs (top five miRNAs and mRNAs are shown on the map). **(B)** Heatmap of differentially expressed miRNAs by RNA sequencing. (RNASEQC, tumor samples of PCC/PGLs patients for RNA sequencing; RNASEQN, normal adrenal medulla tissues of PCC/PGLs patients for RNA sequencing).](fgene-11-00015-g004){#f4}

Kyoto Encyclopedia of Genes and Genomes Pathway Enrichment and Analysis of Differentially Expressed Circular Ribonucleic Acids {#s3_5}
------------------------------------------------------------------------------------------------------------------------------

KEGG pathway analysis revealed that the most enriched pathways were related to insulin secretion, axon guidance, endocytosis, bile secretion, glutamatergic synapse, serotonergic synapse, lysine degradation, and steroid biosynthesis. The top 20 enriched pathways were selected and displayed in a KEGG enrichment scatter plot diagram ([**Figure 5**](#f5){ref-type="fig"}).

![Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis of the differently expressed circular RNAs (circRNAs) and their target gene-related enriched pathways.](fgene-11-00015-g005){#f5}

Prediction and Analysis of the Relationship Between Known Pheochromocytoma and Paraganglioma Susceptibility Genes and the Circular Ribonucleic Acid-Microribonucleic Acid-Messenger Ribonucleic Acid Network {#s3_6}
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The currently known PCC/PGL-related susceptibility genes include *SDHx*, *VHL*, *TMEM127*, *HRAS*, *FGFR1*, *ATRX*, *RET*, *EPAS1*, *MAX*, *EGLN1*, and *NF1* ([@B3]). We thus examined whether the circRNAs exhibit regulatory relationships with the mRNA transcripts of these susceptibility genes. After analyzing and screening the mRNA sequencing data ([**Supplementary Table 5**](#SM1){ref-type="supplementary-material"} mRNA sequencing data of the 7 patients), we selected five differently expressed mRNAs, 88 miRNAs, and 132 circRNAs to map the CNC network. These findings support the role of circRNAs as RNA sponges and in regulating the expression levels of PCC/PGL susceptibility genes ([**Figure 6**](#f6){ref-type="fig"}).

![The competing endogenous RNA network of the known pheochromocytoma and paraganglioma (PCC/PGL) susceptibility genes associated with the circular ribonucleic acid-microribonucleic acid-messenger ribonucleic acid (circRNA-miRNA-mRNA) relationship. Five mRNAs (red), 88 miRNAs (yellow), and 132 circRNAs (green) were included in the analysis.](fgene-11-00015-g006){#f6}

Discussion {#s4}
==========

CircRNA is a special type of highly evolutionarily conserved, regulatory, noncoding RNA, which was originally considered noise or a redundancy of the transcription process ([@B25]). However, an increasing number of studies demonstrated that circRNAs play important roles in various pathological or physiological processes ([@B44]; [@B26]; [@B12]; [@B13]; [@B15]; [@B16]). Studies showed that circRNAs are mainly produced by RNA cleavage, are widely present throughout eukaryotic cells, and have high stability, species conservation, and tissue specificity. CircRNAs are also involved in intracellular RNA regulation networks and are closely associated with the development of many diseases, including systemic sclerosis and several cancer types, such as liver, lung, stomach, oral, nasopharyngeal, ovarian, prostate, uterine, kidney, and bladder cancers ([@B21]; [@B39]; [@B40]; [@B41]; [@B43]; [@B45]; [@B46]). Moreover, it has been reported that circRNAs act as RNA sponges, binding to their corresponding miRNAs to regulate the expression of target genes ([@B25]). Nevertheless, the aberrant expression of circRNAs on a transcriptional level as well as their regulatory functions have not been explored in PCC/PGL patients. Therefore, in this study, we conducted a comprehensive analysis of differentially expressed circRNAs and their potential epigenetic role in PCC/PGLs, subsequently constructing a circRNA-miRNA CNC network that shows the systematic regulatory function of circRNAs in the pathogenesis of PCC/PGLs.

PCC/PGLs are highly genetically related tumors, and thus research on the regulatory function of its transcription processes may further our understanding of PCC/PGL development and better contribute to the diagnosis and treatment of the disease ([@B28]; [@B17]; [@B47]; [@B22]). In the last decades, numerous studies have screened the genetic alterations of PCC/PGLs in an attempt to elucidate the major mutant genes and the disease subtypes caused by those genes ([@B29]; [@B28]; [@B8]; [@B35]; [@B42]; [@B1]). As PCC/PGLs are closely related to epigenetic regulation, comprehensive regulatory network studies are more conducive for explaining their pathogenesis than are studies conducted on a few molecules. Thus, we performed transcriptome analysis of seven PCC/PGL patients *via* RNA sequencing and subsequently identified 3927 mRNAs, 283 miRNAs, and 367 circRNAs that were differentially expressed. We then selected the top 11 differently expressed circRNAs for real-time PCR validation in 33 pairs of tumor tissues and adjacent normal tissues of PCC/PGL patients, and found that the cross-regulated target genes were consistent with the sequencing results.

Some studies have shown that circRNAs can regulate DNA methylation in certain diseases. Wang et al. ([@B27]) reported that CircIBTK can inhibit DNA demethylation and inactivate the AKT pathway in systemic lupus erythematosus patients. Our GO and KEGG pathway analysis of the sequencing results also showed that the major differentially expressed circRNAs were enriched in methylation-related molecular functions such as histone methyltransferase activity and tRNA (cytosine-5-)-methyltransferase activity, which suggests that these circRNAs may affect the development and progression of PCC/PGLs by participating in the modification of target gene methylation. Further analysis of our miRNA sequencing data showed that the histone methylation-related miRNAs predicted by the circRNA-miRNA CNC network were indeed downregulated in tumor tissues, supporting the notion that these circRNAs and miRNAs interact with each other and regulate histone methylation. Moreover, in the KEGG pathway-enriched data, genes with higher enrichment were mainly related to insulin secretion and axon guidance, which coincides with the pathological mechanism of PCC/PGLs patients, wherein neuroendocrine tumors secrete a large amount of catecholamines to disrupt the endocrine and metabolism balance, leading to a series of clinical symptoms such as hypertension and obesity ([@B28]). Therefore, these differentially expressed circRNAs may affect the secretion and metabolism processes of PCC/PGL patients by modulating their target genes. Our findings thus provide new strategies and targets for the diagnosis and treatment of such patients.

It is well known that circRNAs are stable, specific, and abundant ([@B38]; [@B43]; [@B46]), making them suitable for detection as circulating biomarkers in liquid biopsies. Indeed, we identified some differentially expressed circRNAs in PCC/PGL patients, such as hsa_circ_0000567, hsa_circ_0002897, and hsa_circ_0004473, that bind to miRNA and affect histone methylation; these three circRNAs were also found differentially expressed between the peripheral blood of PCC/PGL patients and healthy donors. Previous studies have shown that the hsa-miR-183/182/96 cluster, hsa-miR-21-3p, hsa-miR-551b-3p, and hsa-miR-202-5p are associated with metastatic risk and progression of PCC/PGLs ([@B3]; [@B2]). Notably, our study showed that hsa_circ_0000567 may bind to hsa-miR-96-3p and regulate histone methylation, highlighting hsa_circ_0000567 as a diagnostic and prognostic biomarker for PCC/PGL patients. Meanwhile, *SDHx*, *MEN1*, *RET*, and *HF* susceptibility genes were identified as source genes according to our mRNA sequencing data, after which the circRNA-miRNA-mRNA CNC network of PCC/PGL patients was mapped, providing a basis as well as novel ideas for future PCC/PGL research and diagnostic biomarker discovery.

In conclusion, the present study demonstrated that differentially expressed circRNAs such as hsa_circ_0000567, hsa_circ_0002897, and hsa_circ_0004473 can interact with their target miRNAs and regulate histone methylation during the pathogenesis of PCC/PGLs. KEGG pathway analysis revealed that the differently expressed circRNAs were involved in endocrine-related pathways, consistent with the clinical manifestations of PCC/PGLs. In addition, we identified the circRNAs associated with PCC/PGL susceptibility genes and mapped their regulatory network, which may provide potential prognostic biomarkers and therapeutic targets for PCC/PGL patients.
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